The FDA told the Pink Sheet that it continues granting rare pediatric disease designations, even though those issued after 20 December 2024 will not qualify a product for a priority review voucher. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
